TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01457391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Individual CBT, approx. 12 sessions, one session per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Addiction Counseling
Description: Individual therapy, approx. 12 sessions, one session per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
Study: NCT02171273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Disruption
Description: Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
Study: NCT01398020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bowel Prep
Description: Subjects will be asked to take 4L of Peglyte the day prior to procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L Bi-Peglyte Bowel Prep
Description: Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
Study: NCT03302975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time visual biofeedback during treadmill running
Description: Real-time biofeedback of braking forces during running
Study: NCT03493087

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Menakinon 7
Description: Menakinon 7 - One tablet a day against vitamin K deficiency

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet rich in vitamin K
Description: Diet with large content of vegetables and dairy products
Study: NCT01436084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB1518
Description: 400 mg taken orally, once daily without regard of food, 28 day cycle.
Study: NCT00916279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Paclitaxel-Coated Balloon
Description: PTCA
Study: NCT00856960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Losartan
Description: Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to Aliskiren
Description: Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to Aliskiren
Description: Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to Aliskiren
Description: Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to Losartan
Description: Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo to Losartan
Description: Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to Losartan
Description: Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
Study: NCT01906775

Intervention type: OTHER
Intervention: Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level
Description: Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
Study: NCT03023930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Dissemination Practice
Description: Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation (IF)
Description: IF involves a formative evaluation to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback.
Study: NCT02639611

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Post Operative Acupuncture Treatment
Description: acupuncture treatment immediately after surgery (twice a week for 6 weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Acupuncture Treatment
Description: no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
Study: NCT03543111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zest
Description: Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
Study: NCT03755570

Intervention type: DIAGNOSTIC_TEST
Intervention: Repeatable Assessment of Neuropsychological Status
Description: Cognitive Function Test (Questionnaire-based)

Intervention type: DIAGNOSTIC_TEST
Intervention: Repeatable Assessment of Neuropsychological Status
Description: Cognitive Function Test (Questionnaire-based)

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: Cognitive Function Test (Questionnaire-based)
Study: NCT00658125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral fornix DBS implantation,
Description: Fornix DBS for Alzheimer Disease
Study: NCT04057417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urban Trail
Description: A newly built urban trail that was part of a large policy/infrastructure investment from the city/province to enhance the built environment for active transport and recreational physical activity in the city of Winnipeg, Manitoba Canada between 2010 and 2012.
Study: NCT03755570

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: Cognitive Function Test (Questionnaire-based)

Intervention type: DIAGNOSTIC_TEST
Intervention: Frontal Assessment Battery
Description: Cognitive Function Test (Questionnaire-based)

Intervention type: DIAGNOSTIC_TEST
Intervention: Frontal Assessment Battery
Description: Cognitive Function Test (Questionnaire-based)

Intervention type: DIAGNOSTIC_TEST
Intervention: Trail Making Test Part A and B
Description: Cognitive Function Test (Questionnaire-based)

Intervention type: DIAGNOSTIC_TEST
Intervention: Trail Making Test Part A and B
Description: Cognitive Function Test (Questionnaire-based)

Intervention type: DIAGNOSTIC_TEST
Intervention: Test of Premorbid Functioning
Description: Cognitive Function Test (Questionnaire-based)

Intervention type: DIAGNOSTIC_TEST
Intervention: Test of Premorbid Functioning
Description: Cognitive Function Test (Questionnaire-based)
Study: NCT01357655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
Study: NCT01043341

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educative folder
Description: folder about HPV infection and vaccines

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: educative folder
Description: folder about HPV infection and vaccines
Study: NCT02384668

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
Study: NCT03344419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: Medication infusion intravenously over 1 hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI-581b
Description: Medication infusion intravenously over 1 hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: Manualized one on one therapy aimed at mobilizing motivation for change and for goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Description: Manualized one on one therapy aimed at mobilizing motivation for change and for goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention
Description: Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Relapse Prevention
Description: Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.
Study: NCT04453436

Intervention type: DRUG
Intervention: Tenofovir Disoproxil
Description: Genotipic resistance test

Intervention type: DRUG
Intervention: Tenofovir Disoproxil
Description: Genotipic resistance test
Study: NCT03021499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: calcineurin inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: matching placebo capsule
Study: NCT04422548

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AI-assisted Colonoscopy
Description: This is a multi-center prospective randomized controlled study comparing real-time AI-assisted colonoscopy versus standard colonoscopy in a real-life setting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy
Study: NCT01177436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Taking of urines
Description: Urine specimens collected by vesical catheterism just before surgery. The dosage of PCA-3 and the analyse of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2) will be realized on the samples of urines.
Study: NCT01484977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.~Maximum duration of study drug administration is approximately 23 weeks.
Study: NCT00848133

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mini-midvastus surgical approach for total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mini-subvastus surgical approach for total knee arthroplasty
Study: NCT00450242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% topical lidocaine ointment
Description: Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: hydrophilic petrolatum, dime-sized amount, applied nightly.
Study: NCT00937261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 2mg - 8mg per day, for the duration of participation in the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: 6mg - 12mg per day, for the duration of participation in the study
Study: NCT03207711

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-restricted diet
Description: Education for carbohydrate-restricted diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet
Description: Education for carbohydrate-restricted diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindful eating app-use and instruction
Study: NCT03345823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Oral; Tablet
Study: NCT00282295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra™
Description: Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra™
Description: Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra™
Description: Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
Study: NCT01181076

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individualized Nutrition
Description: The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
Study: NCT00331695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterones caproate
Description: 17 alpha-hydroxyprogesterones caproate
Study: NCT02277015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller Laryngoscope
Description: Direct Laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller Laryngoscope
Description: Direct Laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Berci-Kaplan DCI
Description: Videolaryngoscope-1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Berci-Kaplan DCI
Description: Videolaryngoscope-1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AirTraq
Description: Videolaryngoscope-2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AirTraq
Description: Videolaryngoscope-2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope GVL
Description: Videolaryngoscope-3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope GVL
Description: Videolaryngoscope-3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Pentax AWS
Description: Videolaryngoscope-4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Pentax AWS
Description: Videolaryngoscope-4
Study: NCT00121108

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Motavizumab
Description: Intramuscular dose of motavizumab 15 mg/kg will be administered every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular dose of placebo matched to motavizumab will be administered every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
Study: NCT03588988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine IV infusion
Description: Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
Study: NCT03109379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium-Releasing Intravesical System (TAR-302-5018)
Description: TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium-Releasing Intravesical System (TAR-302-5018)
Description: TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
Study: NCT02108860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
Study: NCT02423551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRE
Description: MRE consumption
Study: NCT00729378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skeletal loading
Description: Impact activities, 3 times per week, increasing the number of jumps (up to 40) and increasing height (from 6 inches to 24 inches per repetition) over the initial 8-weeks (2 months). New activities will be introduced approximately every 2-3 months in order to continually stress the skeleton over 2 years.
Study: NCT01925924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Description: This material contains fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Composite resin
Description: This material does not include fluoride
Study: NCT04383379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention group
Description: The intervention NICUs (n = 6) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes toimprove the rate of breastfeeding . Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.